Therapeutic Asset Ratings

8,587 results matching 1 filter

134,009 assets · 8,804 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
e7386 Colorectal Neoplasm	Eisai Inc.	P1/2	CCC (51)
Eflornithine Advanced Cancer	Aminex Therapeutics, Inc.	P1/2	CCC (51)
Enitociclib NHL	National Cancer Institute (NCI)	P1/2	CCC (51)
Entinostat Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (51)
Enzalutamide Urinary Bladder Carcinoma	Cancer Research UK	P1/2	CCC (51)
Epirubicin Liver Metastases	VA Ann Arbor Healthcare System	P1/2	CCC (51)
Everolimus Acute Myeloid Leukemia	OHSU Knight Cancer Institute	P1/2	CCC (51)
fc084csa tablets Advanced Malignant Solid Tumors	FindCure Biosciences (ZhongShan) Co., Ltd.	P1/2	CCC (51)
Iberdomide Non-Hodgkin Lymphoma	Hoffmann-La Roche	P1/2	CCC (51)
ima203 Refractory Malignant Neoplasm	Immatics US, Inc.	P1/2	CCC (51)
IMMUNOGLOBULIN G1 (149-GLUTAMIC ACID,215-GLUTAMIC ACID,461-ALANINE,462-ALANINE,556-GLYCINE,581-CYSTEINE,593-TRYPTOPHAN), ANTI-(HUMAN CD20 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL RG6026 VH-CH1 FRAGMENT) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 10-AMINO ACID LINKER) FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) (HUMAN-MUS MUSCULUS MONOCLONAL RG6026 HEAVY CHAIN VL(.LAMBDA.)-CH1-CH2-CH3), (222->219''')-DISULFIDE WITH IMMUNOGLOBULIN ANTI-(HUMAN CD20 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL RG6026 .KAPPA.-CHAIN (128-ARGININE,129-LYSINE)) AND (447->232'')-DISULFIDE WITH IMMUNOGLOBULIN ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) (HUMAN-MUS MUSCULUS MONOCLONAL RG6026 LIGHT CHAIN VH-CL(.KAPPA.)), (453->228'), (456->231'), (581->351')-TRIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (149-GLUTAMIC ACID,215-GLUTAMIC ACID,236-ALANINE,237-ALANINE,331-GLYCINE,351-CYSTEINE,368-SERINE,370-ALANINE,409-VALINE) ANTI-(HUMAN CD20 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL RG6026 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RG6026 .KAPPA.-CHAIN (128-ARGININE,129-LYSINE) Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P1/2	CCC (51)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER Urinary Bladder Carcinoma	OncoNano Medicine, Inc.	P1/2	CCC (51)
Ipilimumab Sarcoma	Second Affiliated Hospital of Guangzhou Medical University	P1/2	CCC (51)
Ixazomib Lymphoblastic Lymphoma	Therapeutic Advances in Childhood Leukemia Consortium	P1/2	CCC (51)
Lbl-007 Melanoma	Nanjing Leads Biolabs Co.,Ltd	P1/2	CCC (51)
Ngfr-Transduced Autologous T Lymphocytes Metastatic Melanoma	M.D. Anderson Cancer Center	P1/2	CCC (51)
Pembrolizumab Solid Tumor Cancer	GV20 Therapeutics	P1/2	CCC (51)
Pomalidomide Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P1/2	CCC (51)
TIL Metastatic Malignant Neoplasm	City of Hope Medical Center	P1/2	CCC (51)
Tisagenlecleucel High-grade B-cell Lymphoma	NeoImmuneTech	P1/2	CCC (51)
Tocilizumab Pancreatic Adenocarcinoma	University of Pennsylvania	P1/2	CCC (51)
Tocilizumab Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Jonsson Comprehensive Cancer Center	P1/2	CCC (51)
Toripalimab Advanced Cancer	Wigen Biomedicine Technology (Shanghai) Co., Ltd.	P1/2	CCC (51)
Tumor Antigen Loaded Autologous Dendritic Cells Melanoma	Sichuan University	P1/2	CCC (51)
Ublituximab Waldenstrom Macroglobulinemia	Yazeed Sawalha	P1/2	CCC (51)

Showing 751 to 775 of 8,587 assets

PreviousPage 31 of 344Next